대한치매학회지 (Dementia and Neurocognitive Disorders)

대한치매학회 (Korean Dementia Association)
권호 표지
DOI QR코드

DOI QR Code

Lecanemab: Appropriate Use Recommendations by Korean Dementia Association

  • Kee Hyung Park (Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Geon Ha Kim (Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine) ;
  • Chi-Hun Kim (Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Seong-Ho Koh (Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • So Young Moon (Department of Neurology, Ajou University Hospital, Ajou University School of Medicine) ;
  • Young Ho Park (Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Sang Won Seo (Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Bora Yoon (Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Jae-Sung Lim (Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Byeong C. Kim (Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School) ;
  • Hee-Jin Kim (Department of Neurology, Hanyang University Hospital, Hanyang University College of Medicine) ;
  • Hae Ri Na (Department of Neurology, Bobath Memorial Hospital) ;
  • YongSoo Shim (Department of Neurology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • YoungSoon Yang (Department of Neurology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine) ;
  • Chan-Nyoung Lee (Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Hak Young Rhee (Department of Neurology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine) ;
  • San Jung (Department of Neurology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Jee Hyang Jeong (Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine) ;
  • Hojin Choi (Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Dong Won Yang (Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Seong Hye Choi (Department of Neurology, Inha University Hospital, Inha University College of Medicine)
  • 투고 : 2024.09.30
  • 심사 : 2024.10.23
  • 발행 : 2024.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations, administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.

키워드

과제정보

This work was prepared by the AUR task force team of the Korean Dementia Association and the JOY-ALZ (Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics) project.

참고문헌

  1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023;388:9-21.
  2. U.S FDA. Prescribing information: leqembi [Internet]. Silver Spring: U.S. FDA; 2023 [cited 2024 Sep 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf.
  3. Japanese Ministry of Health Labour and Welfare. Optimal use promotion guidelines lecanemab (genetical recombination) [Internet]. Tokyo: Japanese Ministry of Health Labour and Welfare; 2023 [cited 2024 Sep 30]. Available from: https://www.mhlw.go.jp/content/12404000/001178607.pdf.
  4. Korean Ministry of Food and Drug Safety. Korea product information-lecanemab [M284658] [Internet]. Cheongju: Korean Ministry of Food and Drug Safety; 2024 [cited 2024 Sep 30]. Available from: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202401277aupdateTs2024-09-26%2020:35:39.430968b.
  5. Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 2023;10:362-377.
  6. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 2021;13:80.
  7. Masaki Nakagawa KT, Ogawa T, editors. Clarity AD: analysis in Asian population of a phase III trial of lecanemabin early Alzheimer's disease. The 42nd Annual Meeting of Japan Society for Dementia Research; 2023 Nov 24-26; Nara, Japan.
  8. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
  9. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
  10. Reish NJ, Jamshidi P, Stamm B, Flanagan ME, Sugg E, Tang M, et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med 2023;388:478-479.
  11. Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol 2016;73:197-202.
  12. Salvarani C, Morris JM, Giannini C, Brown RD Jr, Christianson T, Hunder GG. Imaging findings of cerebral amyloid angiopathy, Aβ-related angiitis (ABRA), and cerebral amyloid angiopathy-related inflammation: a single-institution 25-year experience. Medicine (Baltimore) 2016;95:e3613.
  13. Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer's disease: progress to date and the path forward. Neuron 2019;101:820-838.
  14. Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018;14:639-652.
  15. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0 [Internet]. Bethesda: National Cancer Institute; 2017 [cited 2024 Sep 30]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
  16. Barroso A, Estevinho F, Hespanhol V, Teixeira E, Ramalho-Carvalho J, Araujo A. Management of infusion-related reactions in cancer therapy: strategies and challenges. ESMO Open 2024;9:102922.
  17. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-609.
  18. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association research roundtable workgroup. Alzheimers Dement 2011;7:367-385.
  19. Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis 2022;9:211-220.
  20. Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR Jr, Poussaint TY, et al. Amyloid-related imaging abnormalities with emerging alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol 2022;43:E19-E35.
  21. Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, et al. MR imaging features of amyloidrelated imaging abnormalities. AJNR Am J Neuroradiol 2013;34:1958-1965.
  22. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 2020;16:30-42.
  23. Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 2023;146:4414-4424.
  24. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 2013;73:449-458.
  25. Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review. JAMA Neurol 2022;79:291-304.
  26. Jeong SY, Suh CH, Kim SJ, Lemere CA, Lim JS, Lee JH. Amyloid-related imaging abnormalities in the era of anti-amyloid beta monoclonal antibodies for Alzheimer's disease: recent updates on clinical and imaging features and MRI monitoring. Korean J Radiol 2024;25:726-741.
  27. Agarwal A, Gupta V, Brahmbhatt P, Desai A, Vibhute P, Joseph-Mathurin N, et al. Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-amyloid-β therapy. Radiographics 2023;43:e230009.
  28. Charidimou A, Boulouis G, Gurol ME, Ayata C, Bacskai BJ, Frosch MP, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain 2017;140:1829-1850.